Clinical trial

A Study of the Safety and Efficacy of Golimumab in Subjects With Active…

NCT00265083 · Centocor, Inc., Industry · Completed

Key facts

NCT number NCT00265083
Title A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Official title A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis
Lead sponsor Centocor, Inc., Industry
Collaborators Schering-Plough Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Spondylitis, Ankylosing
Intervention type Biological
Interventions golimumab, Golimumab (CNTO 148), placebo
Enrollment 356
Start date Dec 1, 2005
Primary completion Mar 1, 2007
Completion Jan 1, 2012
First posted Dec 14, 2005
Last update posted Jul 19, 2013
Countries Belgium, Canada, Finland, France, Germany, Netherlands, South Korea, Taiwan, United States

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies